Menu
GeneBe

FOXA2

forkhead box A2, the group of Forkhead boxes

Basic information

Region (hg38): 20:22580997-22585455

Previous symbols: [ "HNF3B" ]

Links

ENSG00000125798NCBI:3170OMIM:600288HGNC:5022Uniprot:Q9Y261AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • combined pituitary hormone deficiencies, genetic form (Supportive), mode of inheritance: AD
  • combined pituitary hormone deficiencies, genetic form (Moderate), mode of inheritance: AD

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the FOXA2 gene.

  • not provided (63 variants)
  • Inborn genetic diseases (19 variants)
  • not specified (8 variants)
  • FOXA2-related condition (1 variants)
  • Congenital syndromic hypopituitarism (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the FOXA2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
18
clinvar
6
clinvar
24
missense
1
clinvar
36
clinvar
5
clinvar
6
clinvar
48
nonsense
1
clinvar
1
start loss
0
frameshift
4
clinvar
4
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
0
non coding
1
clinvar
1
Total 0 1 41 24 12

Variants in FOXA2

This is a list of pathogenic ClinVar variants found in the FOXA2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
20-22581844-G-A not specified • FOXA2-related disorder Likely benign (Jan 01, 2023)1338703
20-22581855-A-G Inborn genetic diseases Uncertain significance (Jun 10, 2022)2295118
20-22581870-G-T Uncertain significance (Jun 04, 2022)1971143
20-22581872-C-T Uncertain significance (Nov 08, 2022)1492754
20-22581893-T-A Uncertain significance (Oct 24, 2023)1467399
20-22581905-G-C Inborn genetic diseases Conflicting classifications of pathogenicity (Jan 23, 2024)2283866
20-22581932-G-A Uncertain significance (Jul 14, 2022)2090246
20-22581940-C-G Likely benign (Sep 10, 2022)1920659
20-22581949-G-T Likely benign (Dec 02, 2021)1543591
20-22581969-G-T FOXA2-related disorder Benign (Jan 29, 2024)769996
20-22581995-T-G Inborn genetic diseases Uncertain significance (Jan 22, 2024)2299558
20-22582013-G-A Inborn genetic diseases Uncertain significance (Dec 02, 2022)2372260
20-22582036-T-C Benign (Feb 01, 2024)1300560
20-22582123-T-G Uncertain significance (Jun 29, 2021)2689085
20-22582124-T-A Uncertain significance (Feb 04, 2022)2030270
20-22582134-G-T Inborn genetic diseases Uncertain significance (Jan 29, 2024)3096243
20-22582142-T-G Inborn genetic diseases Uncertain significance (Dec 20, 2023)3096242
20-22582169-G-T Inborn genetic diseases Uncertain significance (Jul 20, 2021)2217278
20-22582189-G-C FOXA2-related disorder Likely benign (Apr 05, 2019)3048214
20-22582206-C-G Uncertain significance (Jun 27, 2022)1927337
20-22582217-G-A Benign (Mar 27, 2023)2960229
20-22582219-C-G Likely benign (Oct 13, 2022)1551896
20-22582234-C-T Likely benign (Nov 25, 2023)2695263
20-22582238-G-C Uncertain significance (Jan 13, 2024)2761574
20-22582241-G-A not specified Conflicting classifications of pathogenicity (Dec 22, 2022)1684750

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
FOXA2protein_codingprotein_codingENST00000419308 24451
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.7420.257125701041257050.0000159
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.3782482650.9350.00001203000
Missense in Polyphen75111.360.673511280
Synonymous-1.801431181.210.00000575922
Loss of Function2.86213.20.1515.70e-7141

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.00003870.0000352
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Transcription factor that is involved in embryonic development, establishment of tissue-specific gene expression and regulation of gene expression in differentiated tissues. Is thought to act as a 'pioneer' factor opening the compacted chromatin for other proteins through interactions with nucleosomal core histones and thereby replacing linker histones at target enhancer and/or promoter sites. Binds DNA with the consensus sequence 5'-[AC]A[AT]T[AG]TT[GT][AG][CT]T[CT]-3' (By similarity). In embryonic development is required for notochord formation. Involved in the development of multiple endoderm-derived organ systems such as the liver, pancreas and lungs; FOXA1 and FOXA2 seem to have at least in part redundant roles. Originally described as a transcription activator for a number of liver genes such as AFP, albumin, tyrosine aminotransferase, PEPCK, etc. Interacts with the cis-acting regulatory regions of these genes. Involved in glucose homeostasis; regulates the expression of genes important for glucose sensing in pancreatic beta-cells and glucose homeostasis. Involved in regulation of fat metabolism. Binds to fibrinogen beta promoter and is involved in IL6-induced fibrinogen beta transcriptional activation. {ECO:0000250}.;
Pathway
Longevity regulating pathway - multiple species - Homo sapiens (human);Maturity onset diabetes of the young - Homo sapiens (human);Heart Development;Cardiac Progenitor Differentiation;Endoderm Differentiation;Dopaminergic Neurogenesis;Mesodermal Commitment Pathway;Ectoderm Differentiation;Liver steatosis AOP;FOXA1 transcription factor network;FOXA2 and FOXA3 transcription factor networks;Hedgehog signaling events mediated by Gli proteins (Consensus)

Recessive Scores

pRec
0.659

Intolerance Scores

loftool
0.0183
rvis_EVS
0.04
rvis_percentile_EVS
56.92

Haploinsufficiency Scores

pHI
0.531
hipred
hipred_score
ghis
0.550

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
1.00

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Foxa2
Phenotype
immune system phenotype; skeleton phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; vision/eye phenotype; reproductive system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; neoplasm; embryo phenotype; liver/biliary system phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan);

Zebrafish Information Network

Gene name
foxa2
Affected structure
exocrine pancreas
Phenotype tag
abnormal
Phenotype quality
decreased size

Gene ontology

Biological process
positive regulation of transcription from RNA polymerase II promoter by glucose;cell fate specification;chromatin organization;regulation of transcription by RNA polymerase II;adult locomotory behavior;anatomical structure morphogenesis;negative regulation of epithelial to mesenchymal transition;cell differentiation;regulation of blood coagulation;endocrine pancreas development;negative regulation of glucokinase activity;positive regulation of embryonic development;negative regulation of DNA-binding transcription factor activity;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;regulation of insulin secretion involved in cellular response to glucose stimulus;negative regulation of transcription from RNA polymerase II promoter by glucose;response to interleukin-6;dopaminergic neuron differentiation;primitive streak formation;positive regulation of cell-cell adhesion mediated by cadherin;positive regulation of gastrulation;negative regulation of detection of glucose
Cellular component
nucleus;nucleoplasm;cytoplasm;cell junction
Molecular function
RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA binding;DNA-binding transcription factor activity;transcription factor binding;protein domain specific binding;transcription regulatory region DNA binding